Canine coronavirus vaccine
AssigneeNorden Laboratories, Inc.
InventorsMichael A. Gill, Stephen W. May
Life of this patent
Estimating the term…
Abstract
A vaccine for protecting canine animals from disease caused by infection with canine corona virus (CCV) which comprises an effective amount of the cell-associated CCV peplomer protein. A polyvalent vaccine comprising an effective amount of cell-associated CCV peplomer protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed.
Claims13
A vaccine for protecting canine animals from disease caused by infection with Canine Coronavirus (CCV) which comprises an effective amount of CCV peplomer protein and which is free for substantially free of CCV virus externalized during culture of infected cells.
A vaccine for protecting canine animals from disease caused by infection with Canine Coronavirus (CCV) which comprises an effective amount of CCV peplomer protein in an inactivated culture of cells infected with CCV from which culture the growth medium has been removed.
A process for producing a vaccine for protecting animals from disease caused by infection with Canine Coronavirus (CCV) which comprises:
- a. infecting a cell culture with a Multiplicity of Infection (MOI) of CCV of at least 0.2to 2;
- b. culturing the cells for 6-18 hours;
- c. discarding the spent fluid medium;
- d. disrupting the cells;
- e. collecting the cell-associated peplomer protein from the disrupted cells;
- and,
- f. combining the cell-associated peplomer with a parenterally acceptable carrier.
Dependencies are inferred from the claim text.